Entera Bio Ltd.   Report issue

For profit Phase 2
Founded: Jerusalem Israel (2010)
Status: No NME R&D (2010)

Organization Overview

First Clinical Trial
2011
NCT02202603
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Entera Bio Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

parathyroid hormone (Natpara) (2 trials)

teriparatide (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypoparathyroidism (Phase 2)

Osteoporosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 2